Big Endothelin-1 (1 – 31) (Human)

Big ET-1 (1-31) (human, bovine)

4360-s 0.1 mg | 198.00 EUR

Synthetic Product (disulfide bonds between Cys¹-Cys¹⁵ and Cys³-Cys¹¹)

Cys – Ser – Cys – Ser – Ser – Leu – Met – Asp – Lys – Glu – Cys – Val – Tyr – Phe – Cys – His – Leu – Asp – Ile – Ile – Trp – Val – Asn – Thr – Pro – Glu – His – Val – Val – Pro – Tyr

The purity is guaranteed to be higher than 99% by HPLC

Big Endothelin-1 (1-31) is an endogenous form of Endothelin-1. The 31 mer oligopeptide is generated by chymase hydolysation from its precursor. This conversation process can be blocked with Phosphoramidon, which is a potent endothelin-converting-enzyme inhibitor. The conversation from Big Endothelin-1 (1-31) into Endothelin 1 will not be effected.

The biological activity of Big Endothelin-1 (1 – 31) is examined by the Division of Pharmacology, Peptide Institute, Inc.

References:

1. A. Nakano, F. Kishi, K. Minami, H. Wakabayashi, Y. Nakaya, and H. Kido, J. Immunol, 159, 1987 (1997) (Original; New Endogenous Form)
2. F. Kishi, K. Minami, N. Okishima, M. Murakami, S. Mori, M. Yano, Y. Niwa, Y. Nakaya, and H. Kido, Biochem. Biophys. Res. Commun., 248, 387 (1998) (Pharmacol.)
3. M. Yoshizumi, D. Inui, N. Okishima, H. Houchi, K. Tsuchiya, H. Wakabayashi, H. Kido, and T. Tamaki, Eur. J. Pharmacol., 348, 305 (1998) (Pharmacol.)
4. M. Yoshizumi, S. Kim, S. Kagami, A. Hamaguchi, K. Tsuchiya, H. Houchi, H. Iwao, H. Kido, and T. Tamaki, Br. J. Pharmacol., 125, 1019 (1998) (Pharmacol.)